Browsing by author "Swain, Amanda"
Now showing items 1-20 of 20
-
A mouse SWATH-mass spectrometry reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts.
Krasny, L; Bland, P; Burns, J; Lima, NC; Harrison, PT; et al. (COMPANY BIOLOGISTS LTD, 2020-06-03)SWATH-mass spectrometry (MS) enables accurate and reproducible proteomic profiling in multiple model organisms including the mouse. Here, we present a comprehensive mouse reference spectral library (MouseRefSWATH) that ... -
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; et al. (ELSEVIER, 2020-11-08)BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ... -
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; et al. (SPRINGERNATURE, 2019-07-11)Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, ... -
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky, AG; Figueiredo, I; Lis, RT; Coleman, I; Gurel, B; et al. (AMER ASSOC CANCER RESEARCH, 2022-08-15)PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown ... -
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; et al. (BMJ PUBLISHING GROUP, 2019-03-21)BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ... -
Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma.
Kerrison, WGJ; Ning, J; Krasny, L; Arthur, A; Guljar, N; et al. (MDPI, 2022-08-04)Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in the advanced setting. Previous synovial sarcoma preclinical studies have relied on a small panel of cell lines which suffer ... -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ... -
Evolutionary selection of alleles in the melanophilin gene that impacts on prostate organ function and cancer risk.
Ermini, L; Francis, JC; Rosa, GS; Rose, AJ; Ning, J; et al. (OXFORD UNIV PRESS, 2021-02-26)BACKGROUND AND OBJECTIVES: Several hundred inherited genetic variants or SNPs that alter the risk of cancer have been identified through genome-wide association studies. In populations of European ancestry, these variants ... -
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt, SJ; Krastev, DB; Brandsma, I; Dréan, A; Song, F; et al. (NATURE PUBLISHING GROUP, 2018-05-01)Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug resistance frequently emerges, often via poorly understood mechanisms. Here, using genome-wide and high-density CRISPR-Cas9 ... -
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.
Pettitt, SJ; Krastev, DB; Pemberton, HN; Fontebasso, Y; Frankum, J; et al. (NATURE PUBLISHING GROUP, 2017-03-01)We describe a screen for cellular response to drugs that makes use of haploid embryonic stem cells. We generated ten libraries of mutants with piggyBac gene trap transposon integrations, totalling approximately 100,000 ... -
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil, V; Miranda, S; Riisnaes, R; Gurel, B; D'Ambrosio, M; et al. (AMER ASSOC CANCER RESEARCH, 2021-12-15)It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that ... -
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; et al. (AMER ASSOC CANCER RESEARCH, 2016-08-01)UNLABELLED: FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level ... -
HOX genes promote cell proliferation and are potential therapeutic targets in adrenocortical tumours.
Francis, JC; Gardiner, JR; Renaud, Y; Chauhan, R; Weinstein, Y; et al. (Springer Science and Business Media LLC, 2021-02-16)BACKGROUND: Understanding the pathways that drive adrenocortical carcinoma (ACC) is essential to the development of more effective therapies. This study investigates the role of the transcription factor HOXB9 and other HOX ... -
Identification of genes that promote PI3K pathway activation and prostate tumour formation.
Francis, JC; Capper, A; Rust, AG; Ferro, K; Ning, J; et al. (SPRINGERNATURE, 2024-06-10)We have performed a functional in vivo mutagenesis screen to identify genes that, when altered, cooperate with a heterozygous Pten mutation to promote prostate tumour formation. Two genes, Bzw2 and Eif5a2, which have been ... -
Pten Regulates Epithelial Cytodifferentiation during Prostate Development.
Lokody, IB; Francis, JC; Gardiner, JR; Erler, JT; Swain, A (PUBLIC LIBRARY SCIENCE, 2015-06-15)Gene expression and functional studies have indicated that the molecular programmes involved in prostate development are also active in prostate cancer. PTEN has been implicated in human prostate cancer and is frequently ... -
Sex specific retinoic acid signaling is required for the initiation of urogenital sinus bud development.
Bryant, SL; Francis, JC; Lokody, IB; Wang, H; Risbridger, GP; et al. (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2014-11-15)The mammalian urogenital sinus (UGS) develops in a sex specific manner, giving rise to the prostate in the male and the sinus vagina in the embryonic female. Androgens, produced by the embryonic testis, have been shown to ... -
SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition.
Francis, JC; Capper, A; Ning, J; Knight, E; de Bono, J; et al. (Impact Journals, LLC, 2018-01-26)Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis and androgen resistance. Understanding the mechanisms by which localised disease progresses to advanced lethal stages is key to the development ... -
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti, J; Sharp, A; Yuan, W; Dolling, D; Nava Rodrigues, D; et al. (AMER ASSOC CANCER RESEARCH, 2018-07-01)Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required. ... -
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti, J; Sharp, A; Brooks, N; Yuan, W; McNair, C; et al. (AMER ASSOC CANCER RESEARCH, 2021-05-01)Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional ... -
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.
Neeb, A; Figueiredo, I; Bogdan, D; Cato, L; Stober, J; et al. (AMER ASSOC CANCER RESEARCH, 2024-06-04)Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain of the AR that drives transcriptional activity in CRPC ...